Literature DB >> 30258095

Optimizing deep response assessment for AL amyloidosis using involved free light chain level at end of therapy: failure of the serum free light chain ratio.

Eli Muchtar1, Angela Dispenzieri1, Nelson Leung1,2, Martha Q Lacy1, Francis K Buadi1, David Dingli1, Suzanne R Hayman1, Prashant Kapoor1, Yi Lisa Hwa1, Amie Fonder1, Miriam Hobbs1, Wilson Gonsalves1, Taxiarchis V Kourelis1, Rahma Warsame1, Stephen J Russell1, John A Lust1, Yi Lin1, Ronald S Go1, Steven R Zeldenrust1, Robert A Kyle1, S Vincent Rajkumar1, Shaji K Kumar1, Morie A Gertz3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30258095     DOI： 10.1038/s41375-018-0258-y

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  9 in total

Review 1.  Systemic amyloidosis: moving into the spotlight.

Authors:  Oliver C Cohen; Ashutosh D Wechalekar
Journal:  Leukemia       Date:  2020-04-09       Impact factor: 11.528

2.  Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA.

Authors:  Giovanni Palladini; Efstathios Kastritis; Mathew S Maurer; Jeffrey Zonder; Monique C Minnema; Ashutosh D Wechalekar; Arnaud Jaccard; Hans C Lee; Naresh Bumma; Jonathan L Kaufman; Eva Medvedova; Tibor Kovacsovics; Michael Rosenzweig; Vaishali Sanchorawala; Xiang Qin; Sandra Y Vasey; Brendan M Weiss; Jessica Vermeulen; Giampaolo Merlini; Raymond L Comenzo
Journal:  Blood       Date:  2020-07-02       Impact factor: 22.113

3.  Characterization and prognostic implication of delayed complete response in AL amyloidosis.

Authors:  Eli Muchtar; Morie A Gertz; Shaji K Kumar; Martha Q Lacy; Nelson Leung; Francis K Buadi; David Dingli; Suzanne R Hayman; Ronald S Go; Prashant Kapoor; Wilson Gonsalves; Taxiarchis V Kourelis; Rahma Warsame; Yi Lisa Hwa; Amie Fonder; Miriam Hobbs; Stephen Russell; John A Lust; Mustaqueem Siddiqui; S Vincent Rajkumar; Robert A Kyle; Angela Dispenzieri
Journal:  Eur J Haematol       Date:  2020-12-04       Impact factor: 2.997

Review 4.  Pathophysiology and Therapeutic Approaches to Cardiac Amyloidosis.

Authors:  Jan M Griffin; Hannah Rosenblum; Mathew S Maurer
Journal:  Circ Res       Date:  2021-05-13       Impact factor: 17.367

Review 5.  Comprehensive Review of AL amyloidosis: some practical recommendations.

Authors:  Rama Al Hamed; Abdul Hamid Bazarbachi; Ali Bazarbachi; Florent Malard; Jean-Luc Harousseau; Mohamad Mohty
Journal:  Blood Cancer J       Date:  2021-05-18       Impact factor: 11.037

Review 6.  Biomarkers in AL Amyloidosis.

Authors:  Despina Fotiou; Foteini Theodorakakou; Efstathios Kastritis
Journal:  Int J Mol Sci       Date:  2021-10-09       Impact factor: 5.923

7.  Detection of minimal residual disease by next generation sequencing in AL amyloidosis.

Authors:  Shayna Sarosiek; Cindy Varga; Allison Jacob; Maria Teresa Fulciniti; Nikhil Munshi; Vaishali Sanchorawala
Journal:  Blood Cancer J       Date:  2021-06-21       Impact factor: 11.037

8.  Comparing measures of hematologic response after high-dose melphalan and stem cell transplantation in AL amyloidosis.

Authors:  Shayna Sarosiek; Luke Zheng; J Mark Sloan; Karen Quillen; Dina Brauneis; Vaishali Sanchorawala
Journal:  Blood Cancer J       Date:  2020-09-01       Impact factor: 11.037

9.  Indicators of profound hematologic response in AL amyloidosis: complete response remains the goal of therapy.

Authors:  Paolo Milani; Marco Basset; Mario Nuvolone; Francesca Benigna; Lara Rodigari; Francesca Lavatelli; Andrea Foli; Giampaolo Merlini; Giovanni Palladini
Journal:  Blood Cancer J       Date:  2020-09-01       Impact factor: 11.037
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.